Douglas Lee, MD
Gastroenterology · Oak Lawn, ILNPI 1144229949
Payments from drug & device makers
Across 41 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$356
- Mauna Kea Technologies, Inc.$226
- Dentsply Sirona Inc$77
- Pfizer$57
- Johnson & Johnson$44
- Takeda Pharmaceuticals U.S.A., Inc.$43
- plus $135 from 5 others
What the payments were for
- Food & beverage$936100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $356 |
| Mauna Kea Technologies, Inc. | 7 | $226 |
| Dentsply Sirona Inc | 1 | $77 |
| Pfizer | 2 | $57 |
| Johnson & Johnson | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Gilead | 2 | $39 |
| Amgen | 1 | $26 |
| Sanofi | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Micro-tech Endoscopy USA, Inc. | 1 | $22 |
How this compares
$936 in reported general payments places this provider in the 40th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 14 | $42,294 |
| Mesalamine | 35 | $10,262 |
| Pantoprazole Sodium | 491 | $8,309 |
| TrulancePlecanatide | 12 | $6,890 |
| Famotidine | 306 | $5,191 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,274 |
| Mesalamine ErMesalamine | 12 | $3,604 |
| Azathioprine | 42 | $2,754 |
| Colesevelam Hcl | 16 | $2,706 |
| Balsalazide Disodium | 24 | $2,037 |
| Cholestyramine LightCholestyramine | 27 | $1,914 |
| Omeprazole | 96 | $1,673 |
| Budesonide DrBudesonide | 18 | $1,205 |
| Hydrocortisone | 32 | $562 |
| Sucralfate | 26 | $539 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Oak Lawn
- Kamran AyubOak Lawn$4.3M
- Charles BerkelhammerOak Lawn$1.9M
- Rogelio SilvaOak Lawn$402K
- David RubinChicago$3.6M
- Jonathan RosenbergGurnee$3.1M
- Stephen HanauerChicago$2.9M
- Parambir DulaiChicago$2.2M
- Ikuo HiranoChicago$1.8M
- Manish BhuvaLake Barrington$1.7M
- Steven FlammChicago$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.